Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK.

Feasibility of a trial to evaluate nicotinamide for chemoprevention of skin cancers in organ transplant recipients in the UK.
Br J Dermatol. 2020 Mar 02;:
Authors: Gollins C, Shah A, Sinha K, Khan S, Paul N, Meeajun B, Abbott RA, Blasdale C, Cooper H, Harwood CA, Ismail F, Lear JT, Mackintosh L, McCormack S, Perrett CM, Proby CM, Durack A, Patalay R, Matin RN
Abstract
Keratinocyte cancers (KC) are the commonest malignancies in the UK population, with rates increasing annually. Nicotinamide (vitamin B3) has recently been reported to reduce the incidence of KC in high-risk patients. It is a precursor of nicotinamide adenine dinucleotide (NAD+) which replenishes cellular energy levels and enhances efficient repair of ultraviolet light (UV) induced DNA damage within keratinocytes.
PMID: 32119116 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - March 1, 2020 Category: Dermatology Authors: Gollins C, Shah A, Sinha K, Khan S, Paul N, Meeajun B, Abbott RA, Blasdale C, Cooper H, Harwood CA, Ismail F, Lear JT, Mackintosh L, McCormack S, Perrett CM, Proby CM, Durack A, Patalay R, Matin RN Tags: Br J Dermatol Source Type: research